MECP2 and Rett syndrome: These recent findings highlight the complexity of mechanisms by which Mecp2 plays its role of transcriptional regulator and partly explains why therapies other than those aimed at correcting/replacing Mecp2 are able to improve only some of the symptoms in patients with RTT (see below).